CliffBio
small molecule

DORYX MPC

DOXYCYCLINE HYCLATE

Loss of exclusivityDecember 2034latest FDA-listed patent expiry
CompanyMAYNE PHARMA INTERNATIONAL PTY LTD

Drug detail

Brand nameDORYX MPC
Active ingredientDOXYCYCLINE HYCLATE
StrengthEQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2016
Marketing statusRX

Listed patents

PatentExpiresType
9446057December 2034product
9295652October 2034product
9511031October 2034product
8715724February 2028product

More from MAYNE PHARMA INTERNATIONAL PTY LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DORYX MPC patent cliff — loss of exclusivity December 2034 | CliffBio